Ajlan Atasoy - Concepedia

Author

Ajlan Atasoy

Istituti di Ricovero e Cura a Carattere Scientifico

Also Known As

Ajlan Atasoy, Annett Maderer

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto USC Norris Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center Candiolo Cancer Institute

About

Ajlan Atasoy is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	149
2	Health Sciences	3	3	115
3	Engineering	1	1	16
4	Anatomy	1	1	18
5	Gastroenterology	1	1	18

Ajlan Atasoy

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer Yi‐Long Wu, Masahiro Tsuboi, Jie He, New England Journal of Medicine	2020	1.7K
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC Yi‐Long Wu, Thomas John, Christian Grohé, Journal of Thoracic Oncology	2021	148
Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer Michael A. Morse, Michael J. Overman, Leighanne Hartman, The Oncologist	2019	113
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel, Journal of Clinical Oncology Checkmate 142First-line TherapyImmunologyPathologyOncology	2020	60
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Journal of Clinical Oncology Clinical EndpointImmunologyPathologyPharmacotherapyLogistic Analysis	2019	39
Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey Vahit Özmen, Ajlan Atasoy, Erhan Gökmen, Cureus	2016	25
Barrett's esophagus and animal models Ryan A. Macke, Katie S. Nason, Ken‐ichi Mukaisho, Annals of the New York Academy of Sciences Be CarcinogenesisGross AnatomyProteomics ScreenEsophagusEsophageal Cancer	2011	18
Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus Robert B. Conley, Dane J. Dickson, Jean C. Zenklusen, Cell OncologyCancer Genomic RepositoriesEngineeringClinical DatabaseMedicine	2017	16
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel, Journal of Clinical Oncology Checkmate 142Cancer ManagementImmunologyPathologyPharmacotherapy	2019	16
Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey Vahit Özmen, Ajlan Atasoy, Erhan Gokmen, Journal of Breast Health	2016	11

Page 1